⌘K
t
On 18 June 2024, BSF Enterprise PLC announced it had received notification from its CFO, Graham Duncan. This notification concerned Duncan's purchase of shares, with specific transaction details referenced in a linked notification of dealing form.
| Date | 18 Jun 2024 |
| Time | 07:00:09 |
| Category | Director/PDMR dealings |
| ID | 8463S |
18 June 2024
BSF Enterprise PLC
("BSF" or the "Company")
NOTIFICATION OF TRANSACTIONS OF DIRECTORS
BSF (LSE: BSFA), (OTCQB: BSFAF), has received notification from its CFO, Graham Duncan, being a person discharging managerial responsibilities, of the purchase of shares as set out in the notification of dealing form here:
http://bsfenterprise.com/wp-content/uploads/2024/06/PDMR_Notification_00380329.pdf
For further enquiries, please visit www.bsfenterprise.com or contact:
|
BSF Enterprise PLC |
Via SEC Newgate below |
|
Geoff Baker - Executive Director Che Connon - CEO & Director |
|
|
Shard Capital (Broker) |
|
|
Damon Heath Isabella Pierre |
0207 186 9000 0207 186 9927 |
|
SEC Newgate (Financial Communications) |
|
|
Bob Huxford Elisabeth Cowell George Esmond |
020 3757 6882 BSF@secnewgate.co.uk |
ISIN of the Ordinary Shares is GB00BHNBDQ51
SEDOL Code is BHNBDQ5.
Notes to Editors
BSF Enterprise PLC (BSF) is focused on unlocking the next generation of biotechnological solutions to deliver sustainable materials and products across a variety of sectors. BSF Enterprise's core technology platform in industrial tissue engineering allows the manufacture at scale of lab-grown alternatives to animal and human tissues, helping deliver sustainable products and materials of the future. The Company's technologies have multiple applications across consumer and medical markets including lab-grown leather, cultivated meat, human corneas and in vitro animal models.
BSF owns 100% of pioneering UK-based tissue engineering companies 3D Bio-Tissues (3DBT), that successfully produced the UK's first high-quality cultivated meat and lab-grown skin from its laboratory and Kerato, a developer of lab-grown corneal replacement tissue for medical and research uses. In addition, it owns 100% of BSF Enterprise (Hong Kong) Limited which is actively supporting commercialisation of our technology in China and Asia.
BSF aims to deliver growth to shareholders through the continued commercialisation and expansion of the Groups IP, which has multiple applications, as well as through M&A. BSF aims to build a comprehensive portfolio in tissue engineering and related applications and license out IP to various stakeholders in the supply chain to enable manufacture at scale and achieve widespread market penetration.